Abstract

Life expectancy is increasing in kidney transplant patients due to improved technology, improved surgical intervention techniques, improved pharmacological approach to management post operatively and better healthcare delivery with improved success rates. However this is not coming without new challenges to address. One of such new challenges is post-transplant diabetes mellitus which has become a common complication of organ transplantation (kidney transplant inclusive) due to the side effects of calcineurin inhibitors, immunosuppressant and steroids used for induction and maintenance of immunosuppression to prevent organ rejection in the transplant recipient.